Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

A nonprofit run by Anne Wojcicki, the cofounder and former CEO of 23andme, has agreed to buy the genetic testing company for $305 million. Wojcicki’s return is likely to spark lawsuits. The nonprofit,

Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a higher bid.